{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:45:53Z","timestamp":1792089953304,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["4R33HL161753-03"],"award-info":[{"award-number":["4R33HL161753-03"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-026-01470-8","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:47:16Z","timestamp":1792086436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In-vivo CRISPR\/Base-Editing \u201cOne-Shot\u201d Therapies Targeting PCSK9"],"prefix":"10.1007","volume":"28","author":[{"given":"Benjamin","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"2","key":"1470_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161\u20135.","journal-title":"Nat Genet"},{"issue":"12","key":"1470_CR2","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372.","journal-title":"N Engl J Med"},{"issue":"11","key":"1470_CR3","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1172\/JCI29383","volume":"116","author":"TA Lagace","year":"2006","unstructured":"Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116(11):2995\u20133005.","journal-title":"J Clin Invest"},{"issue":"2","key":"1470_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2514428","volume":"394","author":"EA Bohula","year":"2026","unstructured":"Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2026;394(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"18","key":"1470_CR5","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"1470_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"16","key":"1470_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"16","key":"1470_CR8","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"issue":"15","key":"1470_CR9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","journal-title":"N Engl J Med"},{"issue":"9","key":"1470_CR10","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","volume":"9","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, et al. Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. JAMA Cardiol. 2024;9(9):800\u20137.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1470_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMoa2511002","volume":"394","author":"AM Navar","year":"2026","unstructured":"Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026;394(6):529\u201339.","journal-title":"N Engl J Med"},{"key":"1470_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.athplu.2024.11.003","volume":"59","author":"N Ferri","year":"2025","unstructured":"Ferri N, Marodin G. Emerging oral therapeutic strategies for inhibiting PCSK9. Atheroscler Plus. 2025;59:25\u201331.","journal-title":"Atheroscler Plus"},{"issue":"21","key":"1470_CR13","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","volume":"85","author":"MJ Koren","year":"2025","unstructured":"Koren MJ, Vega RB, Agrawal N, Xu Y, Barbour AM, Yu H, et al. An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial. J Am Coll Cardiol. 2025;85(21):1996\u20132007.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1470_CR14","doi-asserted-by":"publisher","first-page":"e2412206122","DOI":"10.1073\/pnas.2412206122","volume":"122","author":"H Fang","year":"2025","unstructured":"Fang H, Shi M, Wang C, Zhang S, Kong N, Ji M, et al. PCSK9 potentiates innate immune response to RNA viruses by preventing AIP4-mediated polyubiquitination and degradation of VISA\/MAVS. Proc Natl Acad Sci U S A. 2025;122(8):e2412206122.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1470_CR15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s42003-024-06674-9","volume":"7","author":"A Ghalali","year":"2024","unstructured":"Ghalali A, Alhamdan F, Upadhyay S, Ganguly K, Larsson K, Palmberg L, et al. Contrasting effects of intracellular and extracellular human PCSK9 on inflammation, lipid alteration and cell death. Commun Biol. 2024;7(1):985.","journal-title":"Commun Biol"},{"key":"1470_CR16","doi-asserted-by":"crossref","unstructured":"Lebeau PF, Platko K, Byun JH, Makda Y, Austin RC. The emerging roles of intracellular PCSK9 and their implications in endoplasmic reticulum stress and metabolic diseases. Metabolites. 2022;12(3).","DOI":"10.3390\/metabo12030215"},{"issue":"5819","key":"1470_CR17","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.1138140","volume":"315","author":"R Barrangou","year":"2007","unstructured":"Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709\u201312.","journal-title":"Science"},{"issue":"6096","key":"1470_CR18","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816\u201321.","journal-title":"Science"},{"issue":"4","key":"1470_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41594-022-00756-0","volume":"29","author":"JC Cofsky","year":"2022","unstructured":"Cofsky JC, Soczek KM, Knott GJ, Nogales E, Doudna JA. CRISPR-Cas9 bends and twists DNA to read its sequence. Nat Struct Mol Biol. 2022;29(4):395\u2013402.","journal-title":"Nat Struct Mol Biol"},{"issue":"7490","key":"1470_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature13011","volume":"507","author":"SH Sternberg","year":"2014","unstructured":"Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature. 2014;507(7490):62\u20137.","journal-title":"Nature"},{"issue":"27","key":"1470_CR21","doi-asserted-by":"publisher","first-page":"9798","DOI":"10.1073\/pnas.1402597111","volume":"111","author":"MD Szczelkun","year":"2014","unstructured":"Szczelkun MD, Tikhomirova MS, Sinkunas T, Gasiunas G, Karvelis T, Pschera P, et al. Direct observation of R-loop formation by single RNA-guided Cas9 and Cascade effector complexes. Proc Natl Acad Sci U S A. 2014;111(27):9798\u2013803.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1470_CR22","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1038\/s41467-024-49410-x","volume":"15","author":"D Ben-Tov","year":"2024","unstructured":"Ben-Tov D, Mafessoni F, Cucuy A, Honig A, Melamed-Bessudo C, Levy AA. Uncovering the dynamics of precise repair at CRISPR\/Cas9-induced double-strand breaks. Nat Commun. 2024;15(1):5096.","journal-title":"Nat Commun"},{"issue":"12","key":"1470_CR23","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","volume":"19","author":"HA Rees","year":"2018","unstructured":"Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018;19(12):770\u201388.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"1470_CR24","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1038\/s41467-021-22009-2","volume":"12","author":"MG Kluesner","year":"2021","unstructured":"Kluesner MG, Lahr WS, Lonetree CL, Smeester BA, Qiu X, Slipek NJ, et al. CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells. Nat Commun. 2021;12(1):2437.","journal-title":"Nat Commun"},{"issue":"5","key":"1470_CR25","doi-asserted-by":"publisher","first-page":"e0216674","DOI":"10.1371\/journal.pone.0216674","volume":"14","author":"I Garcia-Tunon","year":"2019","unstructured":"Garcia-Tunon I, Alonso-Perez V, Vuelta E, Perez-Ramos S, Herrero M, Mendez L, et al. Splice donor site sgRNAs enhance CRISPR\/Cas9-mediated knockout efficiency. PLoS ONE. 2019;14(5):e0216674.","journal-title":"PLoS ONE"},{"issue":"4746","key":"1470_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1126\/science.3513311","volume":"232","author":"MS Brown","year":"1986","unstructured":"Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34\u201347.","journal-title":"Science"},{"issue":"12","key":"1470_CR27","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084\u20137.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"1470_CR28","doi-asserted-by":"publisher","first-page":"101436","DOI":"10.1016\/j.omtm.2025.101436","volume":"33","author":"M Hosseini-Kharat","year":"2025","unstructured":"Hosseini-Kharat M, Bremmell KE, Prestidge CA. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism. Mol Ther Methods Clin Dev. 2025;33(1):101436.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"1470_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.bbrc.2004.12.137","volume":"328","author":"X Yan","year":"2005","unstructured":"Yan X, Kuipers F, Havekes LM, Havinga R, Dontje B, Poelstra K, et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun. 2005;328(1):57\u201362.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1470_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514\u201323.","journal-title":"Am J Hum Genet"},{"issue":"7859","key":"1470_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334.","journal-title":"Nature"},{"issue":"3","key":"1470_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee RG, Mazzola AM, Braun MC, Platt C, Vafai SB, Kathiresan S, et al. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models. Circulation. 2023;147(3):242\u201353.","journal-title":"Circulation"},{"key":"1470_CR33","unstructured":"Vafai SB, Gladding PA, Scott R, Turner M, Kastelein JJP, Hegele RA, et al. Safety and pharmacodynamic effects of VERVE-101: an investigational DNA base editing medicine designed to durably inactivate the PCSK9 gene and lower LDL cholesterol \u2013 interim results of the phase 1b heart-1 Trial. In: American Heart Association (AHA) Scientific Sessions 2023; 2023 November 12; Philadelphia, PA."},{"key":"1470_CR34","unstructured":"Bayer M. Verve halts enrollment of lead trial after grade 3 side effects, prioritizing next-up PCSK9 editor. Fierce Biotech. 2024 April 2, 2024."},{"issue":"1","key":"1470_CR35","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1038\/s41467-023-37465-1","volume":"14","author":"LN Kasiewicz","year":"2023","unstructured":"Kasiewicz LN, Biswas S, Beach A, Ren H, Dutta C, Mazzola AM, et al. GalNAc-Lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nat Commun. 2023;14(1):2776.","journal-title":"Nat Commun"},{"key":"1470_CR36","unstructured":"Vafai SB, Taubel J, Ashdown T, Patel RS, Diamondali S, Cegla J et al. In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia. N Engl J Med. 2026."},{"key":"1470_CR37","doi-asserted-by":"crossref","unstructured":"Liao J, Zhang H, Chen S, Hsiao S, Lai C, Feng H, et al. Sequential amino acid mutagenesis-driven de novo evolution of adenine deaminases enables efficient in vivo base editing in primate. bioRxiv; 2025.","DOI":"10.1101\/2025.05.14.653640"},{"key":"1470_CR38","doi-asserted-by":"crossref","unstructured":"Wan P, Tang S, Lin D, Lu Y, Long M, Xiao L et al. Base editing gene therapy for heterozygous familial hypercholesterolemia. medRxiv. 2025:2025.04.17.25325983.","DOI":"10.1101\/2025.04.17.25325983"},{"issue":"3","key":"1470_CR39","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41591-026-04254-4","volume":"32","author":"P Wan","year":"2026","unstructured":"Wan P, Tang S, Lin D, Lu Y, Long M, Xiao L, et al. In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial. Nat Med. 2026;32(3):1045\u201351.","journal-title":"Nat Med"},{"issue":"4","key":"1470_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1702090","volume":"378","author":"JC Kwong","year":"2018","unstructured":"Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345\u201353.","journal-title":"N Engl J Med"},{"key":"1470_CR41","unstructured":"VERVE-102. Heart-2 phase 1b initial data call [press release]. Verve Therapeutics. 2025."},{"key":"1470_CR42","doi-asserted-by":"crossref","unstructured":"Johnson S, Buessing M, O\u2019Connell T, Otu-Adum A, Ciulla TA. Gene therapy and cost-effectiveness analysis: current issues and future research. Med. 2026:101151.","DOI":"10.1016\/j.medj.2026.101151"},{"issue":"8","key":"1470_CR43","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","volume":"2","author":"LD Colantonio","year":"2017","unstructured":"Colantonio LD, Huang L, Monda KL, Bittner V, Serban MC, Taylor B, et al. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JAMA Cardiol. 2017;2(8):890\u20135.","journal-title":"JAMA Cardiol"},{"key":"1470_CR44","doi-asserted-by":"crossref","unstructured":"Ahmad Z, Agarwala A, Cuchel M, Barton Duell P, Hegele RA, Hudgins L et al. Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2026.","DOI":"10.1016\/j.jacl.2026.01.011"},{"issue":"4","key":"1470_CR45","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jacl.2018.04.002","volume":"12","author":"ML Hartgers","year":"2018","unstructured":"Hartgers ML, Besseling J, Stroes ES, Wittekoek J, Rutten JHW, de Graaf J, et al. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. J Clin Lipidol. 2018;12(4):972\u2013e801.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"1470_CR46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","volume":"149","author":"F Raal","year":"2024","unstructured":"Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, et al. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2024;149(5):354\u201362.","journal-title":"Circulation"},{"issue":"19","key":"1470_CR47","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","volume":"128","author":"EA Stein","year":"2013","unstructured":"Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113\u201320.","journal-title":"Circulation"},{"issue":"8","key":"1470_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"1470_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017;377(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"21","key":"1470_CR50","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","volume":"393","author":"LJ Laffin","year":"2025","unstructured":"Laffin LJ, Nicholls SJ, Scott RS, Clifton PM, Baker J, Sarraju A, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. N Engl J Med. 2025;393(21):2119\u201330.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01470-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01470-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01470-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:47:18Z","timestamp":1792086438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01470-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01470-8","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs. Khera is supported by NIH grant 4R33HL161753-03 related to Familial Hypercholesterolemia; Dr. Nelson has no relevant conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects by the authors were used in this study.","order":2,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"100"}}